PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known				
Application Number	to be assigned			
Filing Date February 6, 2002				
First Named Inventor	Uwe Ries			
Art Unit	to be assigned			
Examiner Name	to be assigned			
Attorney Docket Number	5/1266			

			U.S. PATI	ENT DOCUMENTS	
Examiner Initials		Occument Number Number - Kind Code ² (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
140		us- 5,726,159	03/10/1998	Schacht, Aaron L.	
	_	us-			
		us	<u>.</u>	-30-	
		us-			
		us-	!		
		US-			
		us-	-		
	-	us-			
		US-	!		
		US-	ļ		
	_	US-		(.	
	-	US-			·
-		US-			
		US-	<u> </u>	·	
	-	l us- l us-	-		
		lus-	i		
		US-	İ		
	-	l us-	<u> </u>		
		US-	· · ·		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T ⁶			
RO	V	GB-2 007 663 - A1	05/23/1979	VEB Arzneimittelwerl				
-								
j .		. (1) + •	<u> </u>					
				- · · -				
j				- -				

Examiner	liverai	Date Considered	8/15/03
Signature	Mescale	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO				Complete if Known		
					to be assigned	
INFORMATION DISCLOSURE				Filing Date	February 6, 2002	
STATEMENT BY APPLICANT			PPLICANT		Uwe Ries	
			LICAN	Group Art Unit	to be assigned	
	(use as many shee	ets a	s necessary)	Examiner Name	to be assigned	
Sheet	2	of	2	Attorney Docket Number	5/1266	

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²		
Re		SAKAGUCHI, JUN et al; "Synthesis Gastrointestinal Prokinetic Activity and Structure-Activity Relationships of Novel N-[[2-(Dialkylamino)ethoxy]benzyl]benzamide Derivatives"; 1992; Chem. Pharma. Bull. 40(I) 202-211; XP-002152593			
RO		SIMON, L. et al; "Darstellung von substituierten Isochinolinderivaten"; 1974; Pharmazie 29, H. 5 XP-002152594			
Po	-	LABES, D. et al; "Free-Wilson-Analyseder Hemmwirkung von 4-substituierten Benzamidinen gegenueber Thrombin, Plasim und Trypsin"; 1979; Pharamzie 34, H.9 XP002152595,			
			-		
()					
		1			
		,			

Examiner Signature	Roesa	Date Considered	8/15/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether armot citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.